From PsychonautWiki
Jump to navigation Jump to search
Summary sheet: LSM-775
Chemical Nomenclature
Common names LSM-775
Substitutive name Lysergic acid morpholide, N-Morpholinyllysergamide
Systematic name [(8β)-6-Methyl-9,10-didehydroergolin-8-yl](morpholin-4-yl)methanone
Class Membership
Psychoactive class Psychedelic
Chemical class Lysergamide
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 250 µg
Light 500 - 750 µg
Common 750 - 1250 µg
Strong 1250 - 1500 µg
Heavy 1500 µg +
Total 6 - 10 hours
Onset 10 - 30 minutes

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.


Lysergic acid morpholide (also known as N-Morpholinyllysergamide, and LSM-775) is a novel synthetic research psychedelic of the lysergamide chemical class that produces a generally similar albeit significantly less psychoactive array of LSD-like psychedelic effects when administered. It is a close structural homolog of LSD known mainly for its obscurity, low relative potency, and a few comments that have been made on the "dream-like" sedation it produces as well as potential nausea and other potentially uncomfortable physical effects.

LSM-775 was first investigated in animal models in 1957, where it was observed to be "qualitatively similar to LSD" albeit with a significantly lower potency and "half the duration".[1] It was later briefly described as one of the many analogs of LSD by Alexander Shulgin in his book TiHKAL ("Tryptamines I Have Known and Loved"), in which he mentions conflicting reports, with one stating that "75 micrograms is an effective dose, comparable to a similar dose of LSD, and the other stating that "between 350 and 700 micrograms was needed" while producing "fewer signs of cardiovascular stimulation and peripheral toxicity."[2] Since then, it has been observed that the latter observation is a more accurate description of LSM-775's potency in humans, meaning it possesses about 1/10th the potency of LSD.

Very little data exists about the pharmacological properties, metabolism, and toxicity of LSM-775, and it has very little history of human usage. It has recently appeared on the market alongside research chemical psychedelic lysergamides such as AL-LAD, ETH-LAD and PARGY-LAD as a legal, grey-market alternative to LSD, and commercially distributed through online research chemical vendors (although it is considered to be one of the least popular and available in the series). Despite its low observed potency relative to LSD, it is still highly advised to approach this unstudied hallucinogenic substance with the proper amount of precaution and harm reduction practices if one chooses to use it.


Substitutive structure of a lysergamide.

LSM-775, or lysergic acid morpholide, is a synthetic alkaloid of the lysergamide family. LSM-775 is a structural analog of lysergic acid, with a morpholinyl functional group bound to RN of the chemical structure. This core polycyclic structure is an ergoline derivative, and has overlapping tryptamine and phenethylamine groups embedded within it (although it is principally classed as a tryptamine).


Pill bottle-o.png

This pharmacology section is incomplete.

You can help by adding to it.

Further information: Serotonergic psychedelic

LSM-775 likely acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from LSM-775's efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain an object of scientific elucidation.

N-Morpholinyllysergamide (LSM-775) is a derivative of ergine.[1] It is less potent than LSD but is reported to have some LSD-like effects at doses ranging from 75 to 700 micrograms and a shorter duration. There are fewer signs of cardiovascular stimulation and peripheral toxicity with LSM-775 compared to LSD.[2]

Subjective effects

This subjective effects section is a stub.

As such, it is still in progress and may contain incomplete or wrong information.

You can help by expanding or correcting it.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Visual effects

Cognitive effects

Multi-sensory effects

Transpersonal effects


  • Cannabis - When used in conjunction with cannabis, both the visual and cognitive effects of LSM-775 can be intensified and extended with extreme efficiency. This should be used with caution if one is not experienced with psychedelics. Many users sometimes report a dramatically more intense visual trip when combining it with THC concentrates such as hashish as opposed to cannabis flower. However, this can also amplify the anxiety, confusion and psychosis producing aspects of both substances significantly, so extreme caution with this combination is advised.
  • Dissociatives - When used in combination with dissociatives, the geometry, euphoria, dissociation and hallucinatory effects are often greatly enhanced. Dissociative-induced holes, spaces, and voids while under the influence of LSM-775 have significantly more vivid visuals than dissociatives alone present, and more intense internal hallucinations and confusion.
  • MDMA - When used in conjunction with MDMA, the physical and cognitive effects of MDMA are amplified. The visual, physical and cognitive effects of LSM-775 are also intensified with an overwhelming euphoric pleasure manifested through uniquely pleasurable body highs and headspaces, and uniquely colorful and awe-inspiring visuals. It is often recommended to wait at least three to four hours after ingesting LSM-775 to take MDMA so as to avoid coming down from the latter while peaking on the former. The synergy between these substances is unpredictable (and likely neurotoxic)[citation needed], and it is best to start with lower dosages than one would take for both substances individually.
  • Alcohol - This interaction is not typically recommended due to alcohol’s ability to cause dehydration, nausea, and physical fatigue which can negatively affect a trip if taken in in moderate to dosages. This combination is however reasonably safe in low doses and when used responsibly, this can often take the edge off a trip as well as dull its psychedelic effects in a fashion somewhat similar to benzodiazepines, albeit more stressful on the body.
  • Benzodiazepines - When used in combination with benzodiazepines, benzodiazepines can, depending on the dosage, slightly to completely reduce the intensity of the cognitive, physical and visual effects of a LSM-775 trip. They are very efficient at stopping bad trips at the cost of amnesia and reduced trip intensity. Caution is advised when acquiring them for this purpose due to the very high addiction potential that benzodiazepines possess.
  • Psychedelics - When used in combination with other psychedelics, each substance's physical, cognitive and visual effects intensify and synergize strongly. The synergy between those substances is unpredictable, and for this reason generally not advised. If choosing to combine psychedelics, it is recommended to start with lower dosages than one would take for either substance individually.

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational LSM-775 do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because LSM-775 is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried LSM-775 suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

While no formal studies have been conducted, LSM-775 is likely not habit-forming and it is reasonable to speculate that the desire to use it can actually decrease with repeated administratinon. As with most psychedelics, it likely possesses what is considered an intrinsic, self-regulating aspect to it.

Tolerance to the effects of LSM-775 is built almost immediately after ingestion. After that, it takes about 5-7 days for the tolerance to be reduced to half and 14 days to be back at baseline (in the absence of further consumption). LSM-775 likely presents cross-tolerance with all psychedelics, meaning that after the consumption of LSM-775 all psychedelics will have a reduced effect.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

Legal status


This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • Germany: LSM-775 is controlled under the NpSG (New Psychoactive Substances Act)[4] as of July 18, 2019.[5] Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.[6]
  • Switzerland: LSM-775 can be considered a controlled substance as a defined derivative (Alkoxyalkyl) of Lysergic Acid under Verzeichnis E point 263. It is legal when used for scientific or industrial use.[7]

See also

External links


  • Gogerty, J. H., & Dille, J. M. (1957). Pharmacology of d-lysergic acid morpholide (LSM). Journal of Pharmacology and Experimental Therapeutics, 120(3), 340-348. PMID: 13476356


  1. 1.0 1.1 Gogerty, J. H.; Dille, J. M. (1957). "Pharmacology of d-lysergic acid morpholide (LSM)". Journal of Pharmacology and Experimental Therapeutics. 120 (3): 340–348. eISSN 1521-0103. ISSN 0022-3565. OCLC 1606914. PMID 13476356. 
  2. 2.0 2.1 Shulgin, Alexander; Shulgin, Ann (1997). "#26. LSD-25". TiHKAL: The Continuation. United States: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252. 
  3. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039. 
  4. "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019. 
  5. "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020. 
  6. "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019. 
  7. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.